1. Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease 
Veronique S. Chachay, Graeme A. Macdonald, Jennifer H. Martin, Jonathan P. Whitehead, Trisha M. O'Moore–Sullivan, Paul Lee, Michael Franklin, Kerenaftali Klein, Paul J. Taylor, Maree Ferguson, Jeff S. Coombes, Gethin P. Thomas, Gary J. Cowin, Carl M.J. Kirkpatrick, Johannes B. Prins, Ingrid J. Hickman 
Clinical Gastroenterology and Hepatology 
Volume 12, Issue 12, Pages e6 (December 2014)
DOI: /j.cgh
Copyright © 2014 AGA Institute Terms and Conditions

2. Figure 1
Effects of resveratrol on NAFLD characteristic features. (A) IR expressed as M over insulin concentration at 2 hours: [M/I]*100 (medians and interquartile ranges). (B) AT-IR (medians and interquartile ranges). (C) Pre- and post-intervention plasma NEFA suppression during insulin clamp infusion for resveratrol group (means and standard deviations). (D) Pre- and post-intervention plasma NEFA suppression during insulin clamp infusion for placebo group (means and standard deviations). (E) Pre- and post-intervention hepatic steatosis measured by magnetic resonance spectroscopy for resveratrol and placebo groups (medians and interquartile ranges). (F) Pre- and post-intervention abdominal adipose tissue: total (TAT), visceral (VAT), and subcutaneous (SAT) distribution for resveratrol and placebo groups (medians and interquartile ranges). LBW, lean body weight.
Clinical Gastroenterology and Hepatology  , e6DOI: ( /j.cgh )
Copyright © 2014 AGA Institute Terms and Conditions

3. Figure 2
Effect of resveratrol on other metabolic markers. (A) Total adiponectin (medians and interquartile ranges). (B) SA ratio (high molecular weight/total adiponectin). Pre- and post-intervention in resveratrol group, P = .02 (medians and interquartile ranges). (C) IL6 (medians and interquartile ranges). Pre- and post-intervention in resveratrol group, P = .04 (medians and interquartile ranges). (D) Tumor necrosis factor (TNF)-α (medians and interquartile ranges). (E) PTP1B mRNA levels in PBMCs (normalized to actin) of participants in resveratrol group at baseline, week 1, and week 8 (medians and interquartile ranges). (F) NQO1 mRNA levels in PBMCs (normalized to actin) of participants in resveratrol group at baseline, week 1, and week 8 (medians and interquartile ranges).
Clinical Gastroenterology and Hepatology  , e6DOI: ( /j.cgh )
Copyright © 2014 AGA Institute Terms and Conditions

4. Figure 3
Pharmacokinetics of resveratrol up to 6 hours after ingestion of 1500 mg after 8 weeks of 3000 mg daily supplementation (means and standard error of the mean). Cav, concentration average; Cmax, concentration maximum; Cmin, concentration minimum.
Clinical Gastroenterology and Hepatology  , e6DOI: ( /j.cgh )
Copyright © 2014 AGA Institute Terms and Conditions

5. Figure 4
Safety monitoring. ALT (A) and AST (B) weekly fluctuations expressed in percentage change from baseline value (medians and interquartile ranges). (A) Repeated-measures ANOVA. Resveratrol, P = .3; placebo, P = .6. (B) Repeated-measures ANOVA. Resveratrol, P = .5; placebo, P = .8. (C) Plasma cytokeratin-18 fragments for resveratrol and placebo (medians and interquartile ranges). Pre- and postintervention paired t test: resveratrol, P = .1; placebo, P = .2. (D) Plasma high-mobility group box 1 for resveratrol and placebo (medians and interquartile ranges). Pre- and postintervention paired t test: resveratrol, P = .6; placebo, P = .3.
Clinical Gastroenterology and Hepatology  , e6DOI: ( /j.cgh )
Copyright © 2014 AGA Institute Terms and Conditions

6. Supplementary Figure 1 Consort flow diagram.
Clinical Gastroenterology and Hepatology  , e6DOI: ( /j.cgh )
Copyright © 2014 AGA Institute Terms and Conditions

7. Supplementary Figure 2
Resveratrol concentration at weekly reviews in the resveratrol group (medians and interquartile ranges).
Clinical Gastroenterology and Hepatology  , e6DOI: ( /j.cgh )
Copyright © 2014 AGA Institute Terms and Conditions